The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing.
作者信息
Landewé Robert B M
出版信息
Arthritis Rheum. 2003 Jan;48(1):1-5. doi: 10.1002/art.10732.
PMID:12528097
Abstract
摘要
相似文献
1
The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing.类风湿关节炎早期治疗的益处：指征性混杂因素及治疗时机问题。
Arthritis Rheum. 2003 Jan;48(1):1-5. doi: 10.1002/art.10732.
2
[Diagnosis and treatment of early rheumatoid arthritis].[早期类风湿关节炎的诊断与治疗]
Ugeskr Laeger. 2002 Feb 18;164(8):1060-1.
3
How to dose infliximab in rheumatoid arthritis: new data on a serious issue.类风湿关节炎中英夫利昔单抗的给药方法：关于一个重要问题的新数据。
Ann Rheum Dis. 2009 Aug;68(8):1237-9. doi: 10.1136/ard.2009.111682.
4
Timing of DAS28 in infliximab therapy.
Rheumatology (Oxford). 2005 Sep;44(9):1203-4; author reply 1204. doi: 10.1093/rheumatology/keh681. Epub 2005 May 3.
5
Advances in the treatment of early rheumatoid arthritis.早期类风湿关节炎的治疗进展
Am Fam Physician. 2005 Sep 15;72(6):1002, 1004.
6
[Early therapy -- later retirement].
MMW Fortschr Med. 2004 Sep 9;146(37):6, 8.
7
Treatment of rheumatoid arthritis.类风湿关节炎的治疗。
N Engl J Med. 1996 Sep 12;335(11):822; author reply 822-3.
8
[Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Combinations of conventional disease-modifying antirheumatic agents].[甲氨蝶呤耐药类风湿关节炎的循证治疗。传统改善病情抗风湿药的联合应用]
Dtsch Med Wochenschr. 2003 Jan 24;128(4):147-9. doi: 10.1055/s-2003-36869.
9
Diagnosis and management of rheumatoid arthritis.
Am J Med. 2008 Jun;121(6):e7; author reply e9-10. doi: 10.1016/j.amjmed.2007.11.026.
10
[Gold preparations in therapy of rheumatoid and psoriatic arthritis].
Ter Arkh. 2003;75(5):88-90.
引用本文的文献
1
Synovial Fluid Markers and Extracellular Vesicles in Rheumatoid Arthritis.类风湿关节炎中的滑液标志物与细胞外囊泡
Medicina (Kaunas). 2024 Nov 26;60(12):1945. doi: 10.3390/medicina60121945.
2
Serum Peptidomic Profile as a Novel Biomarker for Rheumatoid Arthritis.血清肽组学图谱作为类风湿关节炎的一种新型生物标志物
Int J Rheumatol. 2020 Aug 3;2020:6069484. doi: 10.1155/2020/6069484. eCollection 2020.
3
Production of functional recombinant cyclic citrullinated peptide monoclonal antibody in transgenic rice cell suspension culture.在转基因水稻细胞悬浮培养中生产功能性重组环瓜氨酸肽单克隆抗体。
Transgenic Res. 2019 Apr;28(2):177-188. doi: 10.1007/s11248-019-00113-w. Epub 2019 Feb 11.
4
Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis.接受贝利尤单抗治疗与标准治疗的患者的器官损伤：倾向评分匹配的比较分析。
Ann Rheum Dis. 2019 Mar;78(3):372-379. doi: 10.1136/annrheumdis-2018-214043. Epub 2019 Jan 4.
5
Can Rheumatologists Predict Eventual Need for Orthopaedic Intervention in Patients with Rheumatoid Arthritis? Results of a Systematic Review and Analysis of Two UK Inception Cohorts.风湿病学家能否预测类风湿关节炎患者最终是否需要骨科干预？对两个英国起始队列的系统评价和分析结果
Curr Rheumatol Rep. 2017 Mar;19(3):12. doi: 10.1007/s11926-017-0636-x.
6
Comparative effectiveness research with administrative health data in rheumatoid arthritis.类风湿关节炎的行政健康数据中的比较疗效研究。
Nat Rev Rheumatol. 2016 Jun;12(6):358-66. doi: 10.1038/nrrheum.2016.34. Epub 2016 Apr 15.
7
Decreased serum cell-free DNA levels in rheumatoid arthritis.类风湿关节炎患者血清游离DNA水平降低。
Auto Immun Highlights. 2015 Aug;6(1-2):23-30. doi: 10.1007/s13317-015-0066-6. Epub 2015 Jun 27.
8
Examining radiographic outcomes over time.随时间检查放射学结果。
Rheumatol Int. 2014 Feb;34(2):271-9. doi: 10.1007/s00296-013-2879-9. Epub 2013 Oct 29.
9
MORPHOMETRY FOR EARLY MONITORING OF TREATMENT RESPONSE IN RHEUMATOID ARTHRITIS.类风湿关节炎治疗反应早期监测的形态测量法
Proc IEEE Int Symp Biomed Imaging. 2013:121-124. doi: 10.1109/ISBI.2013.6556427.
10
Anti-citrullinated protein antibodies: role in pathogenesis of RA and potential as a diagnostic tool.抗瓜氨酸化蛋白抗体：在类风湿关节炎发病机制中的作用及其作为诊断工具的潜力。
Rheumatol Int. 2013 Jul;33(7):1669-73. doi: 10.1007/s00296-012-2635-6. Epub 2013 Feb 1.
Zotero 插件